Status:
UNKNOWN
Value of Platelet-Rich Plasma in Post Severe Acute Respiratory Syndrome Coronavirus 2
Lead Sponsor:
Aya abdelnasser hassani
Conditions:
Anosmia
Eligibility:
All Genders
18-75 years
Phase:
EARLY_PHASE1
Brief Summary
The study will be conducted to evaluate : The efficacy of Platelet Rich plasma in treatment of smell disorders post severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) via the growth factors...
Detailed Description
Smell is essential sensory function for good quality of life as its preservation helps in identifying several harmful odors . Viral URTIs can lead to olfactory disorders of varying degree and duratio...
Eligibility Criteria
Inclusion
- patient age above 18 who suffer from anosmia post severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2 more than two weeks
- Normal airway passage
- CT Nose and Para nasal sinuses does not show any nasal lesion
Exclusion
- Lesions obstruct airway as nasal polyps, tumors, chronic sinusitis and severe nasal septum deviation
- Previous Sino nasal surgery
- Atrophic rhinitis
- Diabetic patients and those with medical history of bleeding disorders
- Recieving any medication affect platelets or bone marrow function for 2 weeks prior to testing
Key Trial Info
Start Date :
June 1 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
January 1 2023
Estimated Enrollment :
88 Patients enrolled
Trial Details
Trial ID
NCT05395845
Start Date
June 1 2022
End Date
January 1 2023
Last Update
May 27 2022
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.